Overview

Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-04-27

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Phase:

PHASE3

Details

Lead Sponsor:

Amgen